PD-1 Inhibitor

Introduction Nivolumab is an anticancer immunotherapy marketed under the brand name Opdivo. Pharmacologically, nivolumab is a programmed death receptor-1 blocking antibody, commonly called a PD-1 inhibitor or immune checkpoint inhibitor. Cancer cells can escape immune destruction by activating inhibitory pathways that suppress T-cell function. One of the most important immune escape pathways is the PD-1/PD-L1 … Read more